Seeking Alpha

ThermoGenesis' JV receives $3M equity investment; shares up 13% premarket

|About: ThermoGenesis Holdings, Inc. (THMO)|By: , SA News Editor

ThermoGenesis Holdings (NASDAQ:THMO) is up 13% premarket on the heels of the announcement that ImmuneCyte Life Sciences, an 80/20 joint venture (JV) between HealthBanks Biotech (USA) and ThermoGenesis, has closed a $3M equity investment with a private institution.

The investor received 600,000 Class A common shares at $5.00 per share, representing a 5.66% ownership in JV.

After this investment, ImmuneCyte is owned 75.47% by HealthBanks Biotech, 18.87% by ThermoGenesis and 5.66% by the private institution.

Try Seeking Alpha PREMIUM for unlimited analysis on THMO